3'-SELENOBISALANINE" NO FURTHER A MYSTERY

All enrolled sufferers who been given at the least one dose of zosuquidar or placebo all through induction had been monitored to the occurrence of adverse situations (439 individuals, 219 on zosuquidar and 210 on placebo). The most typical adverse situations were connected with the period of prolonged and sizeable myelosuppression as is expected wi